How many drugs treat H. Influenzae Meningitis?

Drug Landscape tracks 10 marketed treatments for H. Influenzae Meningitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/h-influenzae-meningitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

H. Influenzae Meningitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

H. Influenzae Meningitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating H. Influenzae Meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Chlorocidin	CHLORAMPHENICOL	Parkedale	Amphenicol-class Antibacterial	Cytochrome P450 3A4	1950-01-01
Merrem	Merrem	National Institutes of Health Clinical Center (CC)		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pai Holdings Pharm · 2 drugs in H. Influenzae Meningitis
Pfizer · 2 drugs in H. Influenzae Meningitis
GSK · 1 drug in H. Influenzae Meningitis
Generic (originally Roche) · 1 drug in H. Influenzae Meningitis
National Institutes of Health Clinical Center (CC) · 1 drug in H. Influenzae Meningitis
Parkedale · 1 drug in H. Influenzae Meningitis
Sterimax · 1 drug in H. Influenzae Meningitis
· 1 drug in H. Influenzae Meningitis
Tel-Aviv Sourasky Medical Center · 1 drug in H. Influenzae Meningitis
Centre Hospitalier Universitaire Vaudois · 1 drug in H. Influenzae Meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in H. Influenzae Meningitis:

Cite this brief

Drug Landscape (2026). H. Influenzae Meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/h-influenzae-meningitis. Accessed 2026-06-10.

H. Influenzae Meningitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing